Antiva Biosciences Obtains $16,000,000 Series B Round

  • Feed Type
  • Date
    8/7/2015
  • Company Name
    Antiva Biosciences
  • Mailing Address
    14024 Rue Saint Raphael Del Mar, CA 92014 USA
  • Company Description
    Antiva Biosciences was founded by Karl Hostetler, M.D., a leader in virology who founded Chimerix, Triangle Therapeutics (acquired by Gilead) and Vical. The company is using a new medicinal chemistry platform to develop antiviral therapies, focusing first on HPV. Antiva has additional molecules that target HIV, the herpes virus, cytomegalovirus and others.
  • Website
    Undisclosed
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $16,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the financing will be used to advance Antiva’s lead compound, ABI-1968, through Phase 1 clinical trials.
  • M&A Terms
  • Venture Investor
    Canaan Partners
  • Venture Investor
    Sofinnova Ventures

Trending on Xconomy